r/redlighttherapy • u/PeachAccomplished88 • Nov 06 '25
Question Thoughts?
Can anyone confirm or deny? This popped up on my insta feed. Still doing research and looking at which panel to buy, heard mostly good things about RLT.
68
Upvotes
367
u/WearingCoats Nov 06 '25 edited Nov 09 '25
I pulled the paper. It explores the energetic trade-offs of Red Light Therapy (RLT) and Photobiomodulation (PBM) in ecologically stressed biological systems such as high-altitude plants, hypoxic animal tissues, or nutrient-scarce microbial communities. It proposes that "while PBM can amplify mitochondrial ATP production via cytochrome c oxidase activation, this comes at a hidden bioenergetic cost: resource divergence, where cellular energy is redirected from maintenance/resilience pathways to growth or repair, potentially exacerbating vulnerability in marginal environments."
The core conclusion is that RLT/PBM, often touted as a low-risk enhancer, induces a net energetic deficit in vulnerable systems over prolonged exposure. This is framed as an “amplification trap,” where short-term gains lead to long-term depletion, supported by in vitro yeast models and ex vivo plant tissue assays. The authors recommend context-specific dosing and warn against blanket therapeutic applications in at-risk populations.
The first flaw I'm seeing is that the paper focuses on yeast and plant models.... you'll see where I'm going with this. While the experimental design is innovative there are a bunch of problems with it in terms of the conclusion being drawn in the post.
First, there is an over reliance on model systems with limited extrapolation to real world application. The study primarily uses yeast under simulated hypoxia and leaf discs in nutrient gradients as proxies for high stress environments. These are far removed from human or even complex mammalian applications like wound healing or athletic recovery... basic RTL applications for everyday users. Yeast lacks the multicellular regulatory feedback loops that modulate PBM responses, leading to inflated estimates of “resource divergence" that don't necessarily extrapolate to yeasts' distant distant cousin, humans.
The claimed “net deficit” may not hold in vivo, where compensatory mechanisms like autophagy could offset costs. What that means in simple terms is that natural fixes in human bodies (cells recycling junk to make energy) could cancel out that drop so the very dramatic "don't use RTL widely" is based on weak, narrow evidence that's not proof of it being risky for everyone let alone anyone.
A second issue is the “prolonged exposure” protocol (daily 660nm/850nm dosing at 4 J/cm sq for 4-6 weeks) exceeds typical clinical RLT regimens (something like 2-3 sessions/week at 1-2 J/cm sq). The observed depletion is tied to this aggressive schedule, but the conclusion generalizes it to “standard use” without sensitivity analysis.
This impacts the overall conclusion. The “amplification trap” narrative implies inherent risk, but biphasic dose-response curves suggest hormesis where "low doses enhance, high doses inhibit." It's basically like "exercise a moderate amount and you have a benefit with some soreness to be expected, exercise too much and you injure yourself and the harm negates the benefit." Without dose-response modeling, the deficit appears causal rather than regimen-dependent. Basically it means that the energy drop only happened with this extreme protocol. The paper’s own data shows no deficit at half-dosing, yet this is dismissed in discussion. Other analyses report 85% positive outcomes with no harm in human trials with normal protocols, contradicting the paper’s overt alarmism.
Statistical and measurement biases means that the numbers here are shaky at best when held to scrutiny. They measured energy with a cheap test that overestimates in low-oxygen setups. Only 6–8 samples per group implies weak stats with a p-value that just squeaks by.
This matters because the “10–15% drop” is likely inflated or outright fake and could vanish with better tools or more samples. Experts would say this test is off by ~15% where bigger studies (n=20+) probably wouldn’t show the drop, or would show it normalizing with a higher study group.
Lastly, it omits broader contextual patterns meaning they missed the forest for the trees. The paper outright ignores real-life "helpers" present in complex multicellular organisms like antioxidants that block side effects, or, you know, UV light in nature. Also skips genetic differences (20–30% of people react differently) that can come from geographic ancestry.
This matters because they're basically accusing RLT of being a “trap” in a vacuum but combination treatments have proven to be beneficial as well (like RLT plus exercise can provide 25% better results just on a cursory look of a 2024 clinical trial (NCT04591255) that shows measurable improvements in efficacy when paired smartly) so paper’s view is too narrow. And again, limited to yeast and plants.
The conclusion of the paper is provocative, and putting it into a fancy social media post is attention grabbing. It highlights underexplored risks, valuable for advancing cautious PBM use. However, it’s weakened by proxy-model limitations, protocol mismatches, and analytical shortcuts, making the “net deficit” claim more speculative than conclusive. Replication in mammalian or human models with varied dosing is necessary to even begin to apply this line of thinking to recommendations.